CRBU Q1 2024 Earnings — Caribou Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CRBUCaribou Biosciences, Inc.

$186M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-30.6% YoY

Gross Profit

$2M70.8% margin

Operating Income

-$46M-1893.9% margin

Net Income

-$41M-1697.6% margin

EPS (Diluted)

$-0.46

QoQ Revenue Growth

-31.7%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$40M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$407M

Total Liabilities

$64M

Stockholders' Equity

$343M

Cash & Equivalents

$49M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$4M	-30.6%
Gross Profit	$2M	-$22M	+107.7%
Operating Income	-$46M	-$31M	-47.8%
Net Income	-$41M	-$28M	-47.0%

Geographic Segments

UNITED STATES

$2M93%

Non-US

$160,0007%